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Background: Genetic factors play an important role in the pathogenesis of coronary heart disease (CHD).
Kinesin-like protein 6 (KIF6) is a new candidate gene for CHD, since it has been identified as a potential risk
factor. The aim of this study was to perform a systematic review and meta-analysis of previously published
association studies between the Trp719Arg polymorphism of KIF6 and the development of CHD.
Methods: Studies and abstracts investigating the relationship between the Trp719Arg polymorphism of KIF6
and subsequent risk for development of CHD were reviewed. Electronic search from Pubmed and EBSCO
databases was performed between 1993 and 2014 to identify studies that fulfilled the inclusion criteria. To
analyze the association we used the models: allelic, additive, dominant and recessive. Moreover, we
conducted a sub-analysis by populations using the same four models.
Results: Twenty-three studies were included in the meta-analysis. The Trp719Arg polymorphism showed a
significant association with CHD when the analysis comprised the population with myocardial infarction (MI)
and the additive genetic model was used. Moreover, this polymorphism showed a protective association with
CHD when the analysis comprised the whole population using the recessive genetic model.
Conclusions: Our findings indicate that the Trp719Arg polymorphism of the KIF6 gene is an important risk
factor for developing MI and that allele 719Arg may have a protective association to present CHD in all
populations.
PROSPERO registration: CRD42015024602.
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The risk for coronary heart disease (CHD) is influ-
enced by both environmental and genetic factors and
often it is initially detected from clinical manifesta-
tions such as angina, myocardial infarction or sudden
death due to artery occlusion [1]. Several environ-
mental factors, such as obesity, oxidative stress,
alcoholism, smoking and lack of exercise have been* Correspondence: thelma.glez.castro@gmail.com
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years, multiple genetic analysis studies have identified
several loci and variants that are strongly associated
with CHD [2, 3]. Kinesin-like protein 6 (KIF6) is
considered a candidate gene for CHD, since it has
been identified as a potential risk factor in European
populations [4, 5]. KIF6 is a member of a family of
molecular motors involved in intracellular transport
of protein complexes, membrane organelles, and
messenger ribonucleic acid along microtubules. This
gene spans a genomic region of about 390,000 base pairs
at human chromosome 6p21; moreover, it is ubiquitously
expressed in coronary arteries and other vascular tissuerticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Ruiz-Ramos et al. Hereditas  (2015) 152:3 Page 2 of 16[6, 7]. To date, multiple large prospective and case–con-
trol studies have reported an association of a common
KIF6 gene polymorphism—Trp719Arg single nucleotide
polymorphism (SNP) (rs20455)— with CHD risk. Carriers
of the 719Arg allele exhibit a 50 % increased risk of events
compared with non-carriers [5, 8]. However, some
studies have not verified this conclusion. In view of
the discrepancies in the findings of previous published
studies, we aimed to perform a systematic review and
meta-analysis to clarify the association between
Trp719Arg in KIF6 and CHD to get a better under-
standing of this relationship.Methods
The meta-analysis and systematic review were performed
by following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) criteria [9, 10].
The PRISMA checklist is included as Additional file 1.
PROSPERO registration: CRD42015024602.Identification and selection of publications
To perform the meta-analysis, we systematically searched
for available articles in multiple electronic databases. The
literature search was conducted using PubMed and
EBSCO databases. Relevant studies were identified using
the terms: “Kinesin 6 AND polymorphisms AND cardio-
vascular heart disease”, “KIF6 AND polymorphisms AND
cardiovascular heart disease”, “KIF6 AND polymorphisms
AND CHD”, “KIF6 AND Trp719Arg AND cardiovascular
heart disease” and “KIF6 AND Trp719Arg AND CHD”.
These words were combined to retrieve the summaries.
The search also implicated the review of the bibliography
cited at the end of the various research articles.Inclusion and exclusion criteria
Two researchers (González-Castro and Hernández-
Díaz) working independently screened each of the
titles, abstracts and full texts to determine inclusion.
When the researchers were in disagreement a third
researcher (Tovilla-Zárate) was consulted. Studies
were included if they met the following criteria: (1) to
be published in peer-reviewed journals, (2) to have a
case–control study design, (3) to contain independent
data, (4) to be association studies in which the
frequencies of three genotypes were clearly stated or
could be calculated, (5) to include diagnosis of a
cardiovascular disease in the patient study group, and
(6) the articles had to be written in English. Studies
were excluded when: (1) they were not case–control
studies, (2) they were reviews, comments or editorial
articles, (3) provided insufficient data, and (4) they
were repeated studies.Data extraction
The same authors mentioned previously extracted the
information from all the included reports and reached
consensus on all the items. The following data were
obtained from each of the studies: authors, year of publi-
cation, location, ethnic group, number of cases and/or
controls, age, gender and cardiovascular diagnosis of the
participants. If these data were not available in the
studies, the corresponding author of the respective art-
icle was contacted.
Evaluation of statistical associations
For the meta-analysis, the odds ratio (OR) and 95 %
confidence interval (CI) values were estimated and
used to evaluate the strength of the association of
KIF6 Trp719Arg polymorphisms with CHD risk.
Pooled ORs were calculated following four genetic
models: dominant (A/G + A/A vs G/G), recessive (G/
G + A/G vs A/A), additive (A/A vs G/G) and allelic
(A vs G). The EPIDAT 3.1 program (http://dxsp.ser-
gas.es) used for this part is freely available for epide-
miologic analysis of tabulated data. On the other
hand, to explore the problem of publication bias, the
Egger’s test and funnel plots were calculated with the
same software. This last approach standardizes the ef-
fect of each of the published studies on the vertical
axis and its correspondent precision on the horizontal
axis. Sample heterogeneity was analyzed with the Der-
simonian and Laird’s Q test. Q test results were com-
plemented with graphs to help the visualization of those
studies favoring heterogeneity. For all these procedures we
used the above-mentioned program. Moreover, to aboard
the problem of a small sample size we performed a
meta-regression based in ages; this analysis was car-
ried out in the comprehensive meta-analysis software
version 2. Next, a chi-squared (χ2) analysis was used
to calculate the Hardy-Weinberg equilibrium to evalu-
ate genotype distribution. In order to strengthen the
analysis we evaluated publication bias by using the
GRADE approach and assessed the risk of bias. The
Newcastle-Ottawa Assessment Scale (NOS) was used
for inclusion in the systematic review by scoring the
methodological quality. We established a score of six
as cut-off point to distinguish high from low quality
studies [11] (see Additional file 2).
Results
Studies included in the meta-analysis
The electronic searches yielded 34 potentially relevant
studies. From these 6 reports were excluded because
they consisted of duplicated publications, hence 28
studies were potentially relevant for inclusion in our
study; 5 studies were further excluded because either
the Trp719Arg genotype was not detected or the
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end, a total of 23 articles met the inclusion criteria
(Fig. 1) [12, 13]. The overall study population
included in the current meta-analysis consisted of
38,906 subjects, of which 17,812 were cases and
21,094 controls. We divided the included studies into
sub-groups according to their diagnosis: coronary
artery diseases (CAD) population (5235 patients, 6682
controls) and myocardial infarction (MI) population
(12,577 patients, 14,412 controls), and another section
in accordance with ethnicity: Caucasians (12,897
patients, 14,897 controls). The characteristics of the
included studies are summarized in Tables 1 and 2.
The included studies (n = 23) were published between
1993 and 2014.
Analysis of the association between the KIF6 Trp719Arg
polymorphism and CHD in all populations
The association between the Trp719Arg polymorph-
ism and susceptibility to CHD was analyzed in 23Fig. 1 Flow-chart showing the search strategy and inclusion/exclusion criteindependent studies. The results of the meta-analysis
in the correlation between CHD and Trp719Arg
polymorphism in 23 case–control studies are shown
in Fig. 2. There was no inter-study heterogeneity
among overall studies of the Trp719Arg polymorph-
ism in all four genetic models (allelic, additive, dom-
inant and recessive). We used the random-effects
model, which yielded a slight association in the re-
cessive genetic model (OR: 0.59, 95 % CI: 0.54–0.63;
Q test: 0.05; Egger’s test: 0.71). However, no signifi-
cant association was observed when all the popula-
tions were considered in the analysis using the other
genetic models (allelic: OR: 1.02, 95 % CI: 0.98–1.05;
Q test: 0.16; Egger’s test: 0.45; additive: OR: 1.05,
95 % CI: 0.98–1.13; Q test: 0.24; Egger’s test: 0.33,
and dominant: OR: 1.03, 95 % CI: 0.98–1.09; Q test:
0.06; Egger’s test: 0.39) (Tables 3 and 4; Fig. 3). With
regard to the meta-regression performed based on
the ages of the whole population, the analysisria used in the meta-analysis and systematic review
Table 1 Descriptive characteristics of the association studies on the Trp719Arg polymorphism of the KIF6 gene and CHD included in the meta-analysis and systematic review
Author Year Country Ethnicity Number Diagnosis Mean age
Cases Control Cases Control
Berglund, G. [17] 1993 Sweden Caucasians 86 99 MI 48.5 48.7
Vartiainen, E. [18] 2000 Finland Caucasians 167 172 MI 47.1 47.1
Senti, M. [19] 2001 Spain Caucasians 312 317 MI 45.9 46.0
Yusuf, S. [20] 2004 Bangladesh, Sri Lanka,
Pakistan, others.
Asians 1092 1187 MI 51.4 49.8
Low, A. F. [21] 2005 USA Caucasians 204 260 MI 47.0 53.8
Helgadottir, A. [22] 2007 USA Caucasians 875 447 CAD 48.9 59.8
Helgadottir, A. [22] 2007 USA Caucasians 933 468 CAD 52.7 61.7
Samani, N. J. [23] 2007 Germany Caucasians 1126 1277 MI 51.3 51.2
Samani, N. J. [23] 2007 Germany Caucasians 722 1643 MI 50.2 62.5
Meng, W. [24] 2007 Northern Ireland Caucasians 482 622 MI 46.0 55.2
Iakoubova, O. [14] 2008 USA Caucasians 276 519 MI 56.4 56.2
Meiner, V. [25] 2008 USA Caucasians 505 559 MI 46.0 45.2
Serre, D. [26] 2008 Several Several 789 859 MI 61.6 61.2
Morgan, T. M. [27] 2008 USA Caucasians 807 637 MI 61.5 60.7
Assimes, T. L. [28] 2008 USA Caucasians 505 514 CAD 45.4 45.6
Vennemann, M. M. [29] 2008 Germany Caucasians 793 1121 MI 52.2 52.6
Sutton, B. S. [30] 2008 USA Caucasians 1575 970 MI 28.9 52.4
Martinelli, W. [31] 2008 Italy Caucasians 1106 383 CAD 61.4 58.0
Herrera-Galeano, J. E. [32] 2008 USA Caucasians 378 2652 CAD 46.9 47.2
Stewart, A. F. [33] 2009 Canada Caucasians 1540 1455 MI 49.0 75
Luke, M. M. [34] 2009 Austria Caucasians 505 782 CAD 66.0 58.8
Bare, L. A. [13] 2010 Costa Rica Latin-Americans 1987 2147 MI 58.3 58.3
Wu, G. [16] 2012 China Asians 356 568 CAD 64.9 60.3
Wu, G. [16] 2012 China Asians 114 568 MI 64.9 60.3
Peng, P. [15] 2012 China Asians 289 522 CAD - -











Table 2 Genotype and allele distribution in association studies on the Trp719Arg polymorphism of the KIF6 gene with CHD
Author Genotype cases Genotype controls Allele cases Allele controls HWE
Trp/Trp Trp/Arg Arg/Arg Trp/Trp Trp/Arg Arg/Arg Trp Arg Trp Arg Cases p value Controls p value
Berglund, G. [17] 35 38 13 33 54 12 108 64 120 78 0.64 0.20
Vartiainen, E. [18] 64 81 22 73 76 23 209 125 222 122 0.74 0.62
Senti, M. [19] 134 139 39 141 137 39 407 217 419 215 0.80 0.53
Yusuf, S. [20] 351 498 243 389 531 267 1200 984 1309 1065 0.09 0.06
Low, A. F. [21] 89 86 29 114 111 35 264 144 339 181 0.53 0.34
Helgadottir, A. [22] 370 399 106 174 221 52 1139 611 569 325 0.94 0.18
Helgadottir, A. [22] 359 441 133 194 213 61 1159 707 601 335 0.59 0.84
Samani, N. J. [23] 447 529 150 522 593 162 1423 829 1637 917 0.79 0.80
Samani, N. J. [23] 293 328 101 662 753 228 914 530 2077 1209 0.57 0.55
Meng, W. [24] 203 226 53 261 292 69 632 332 814 430 0.42 0.37
Iakoubova, O. [14] 104 137 35 256 204 59 345 207 716 322 0.36 0.06
Meiner, V. [25] 187 228 90 216 260 83 602 408 692 426 0.16 0.78
Serre, D. [26] 335 337 117 354 402 103 1007 571 1110 608 0.03* 0.55
Morgan, T. M. [27] 322 377 108 256 304 77 1021 593 816 458 0.93 0.39
Assimes, T. L. [28] 162 187 83 144 183 130 511 353 471 443 0.03* 0.00*
Vennemann, M. M. [29] 311 379 103 430 528 163 1001 585 1388 854 0.44 1.00
Sutton, B. S. [30] 545 570 183 297 347 86 1660 936 941 519 0.09 0.33
Martinelli, W. [31] 437 501 168 145 191 47 1375 837 481 285 0.22 0.22
Herrera-Galeano, J. E. [32] 106 148 31 626 752 201 360 210 2004 1154 0.05 0.30
Stewart, A. F. [33] 183 695 662 205 616 634 1061 2019 1026 1884 1.00 0.00*
Luke, M. M. [34] 73 254 178 102 373 307 400 610 577 987 0.26 0.53
Bare, L. A. [13] 785 952 250 896 966 285 2522 1452 2758 1536 0.13 0.33
Wu, G. [16] 104 164 88 168 268 132 372 340 604 532 0.16 0.20
Wu, G. [16] 16 68 30 168 268 132 100 128 604 532 0.03* 0.20
Peng, P. [14] 69 149 71 139 262 121 287 291 540 504 0.63 0.93
Wu, G. [35] 74 141 73 101 166 79 289 287 368 324 0.72 0.51











Fig. 2 Odds ratios and forest plots of the Trp719Arg polymorphism in overall studies without heterogeneity using the following models:
a) Allelic, b) Additive, c) Dominant and d) Recessive
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p-value of 0.722 (Fig. 4).
Analysis of the association between the KIF6 Trp719Arg
polymorphism and CHD in CAD populations
Information about 9 cases of coronary artery diseases
(CADs) was available in 5235 patients. The analysis
of CAD populations did not show a significant asso-
ciation between the Trp719Arg polymorphism of theKIF6 gene and CHD using the random effects model
in all four genetic models (allelic model: OR: 0.98,
95 % CI: 0.90–1.07; Q test: 0.05; Egger’s test: 0.58;
additive model: OR: 0.98, 95 % CI: 0.82–1.16; Q
test: 0.06; Egger’s test: 0.32; dominant model: OR:
0.98, 95 % CI: 0.89–1.08; Q test: 0.32; Egger’s test:
0.63, and recessive model: OR: 0.97, 95 % CI: 0.83–
1.13; Q test: 0.05; Egger’s test: 0.35) (Table 3; Figs. 5
and 6).
Table 3 Analysis of association studies on the Trp719Arg polymorphism of the KIF6 gene with CHD in all populations, CAD populations, MI populations and Caucasian
populations in this study
Model analysis All populations CAD MI
Random effects

















Allelic With heterogeneity - - - - - -
Without heterogeneity 1.02(0.98–1.05) 0.16 0.45 0.98(0.90–1.07) 0.05 0.58 1.03(0.99–1.07) 0.59 0.14
Additive With heterogeneity - - - - - -
Without heterogeneity 1.05(0.98–1.13) 0.24 0.33 0.98(0.82–1.16) 0.06 0.32 1.08(1–00–1.16) 0.69 0.10
Dominant With heterogeneity - - - - - -
Without heterogeneity 1.03(0.98–1.09) 0.06 0.39 0.98(0.89–1.08) 0.32 0.63 1.06(0.98–1.13) 0.05 0.23
Recessive With heterogeneity - - - - - -











Table 4 Analysis of association studies on the Trp719Arg polymorphism of the KIF6 gene with CHD in all populations, CAD
populations, MI populations and Caucasian populations in this study
Model analysis Caucasians
Random effects OR (CI 95 %) P value of Q test P value of Egger’s test
Allelic With heterogeneity - - -
Without heterogeneity 1.00(0.96–1.05) 0.14 0.99
Additive With heterogeneity - - -
Without heterogeneity 1.02(0.94–1.12) 0.28 0.87
Dominant With heterogeneity - - -
Without heterogeneity 1.01(0.95–1.08) 0.18 0.99
Recessive With heterogeneity - - -
Without heterogeneity 1.00(0.92–1.08) 0.23 0.48
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polymorphism and CHD in MI populations
Subsequently, we explored this SNP in patients with
MI and the analysis indicated that the Trp719Arg
polymorphism of the KIF6 gene was significantly
associated with CHD only in the additive model
(Random effects: OR: 1.08, 95 % CI: 1.00–1.16; Q
test: 0.69; Egger’s test: 0.10) (Table 3; Figs. 7 and 8).
The other genetic models did not show a significant
association between these two parameters (allelic: OR:
1.03, 95 % CI: 0.99–1.07; Q test: 0.59; Egger’s test:
0.14; dominant: OR: 1.06, 95 % CI: 0.98–1.13; Q test:
0.05; Egger’s test: 0.23, and recessive: OR: 1.03, 95 %
CI: 0.96–1.10; Q test: 0.89; Egger’s test: 0.06) (Table 3;
Figs. 7 and 8). On the other hand, the meta-
regression analysis based on the age of the patients
who had MI showed a point estimate slope of
0.00379 and a p-value of 1.242 (Fig. 9).
Analysis of the association between the KIF6 Trp719Arg
polymorphism and CHD in Caucasian populations
The analysis in Caucasian populations did not show a
significant association between the Trp719Arg poly-
morphism of the KIF6 gene and CHD in all four
genetic models (allelic model: OR: 1.00, 95 % CI:
0.96–1.05; Q test: 0.14; Egger’s test: 0.99; additive
model: OR: 1.02, 95 % CI: 0.94–1.12; Q test: 0.28;
Egger’s test: 0.87; dominant model: OR: 1.01, 95 %
CI: 0.95–1.08; Q test: 0.18; Egger’s test: 0.99, and re-
cessive model: OR: 1.00, 95 % CI: 0.92–1.08; Q test:
0.23; Egger’s test: 0.48) (Table 4; Figs. 10 and 11).
Discussion
In this study, we explored the relationship between
the Trp719Arg polymorphism of the KIF6 gene and
CHD given that several lines of evidence have shown
an association between the Trp719Arg polymorphismand increased risk of CHD in the placebo groups of
some clinical trials such as the Cholesterol and
Recurrent Events (CARE) study and the West of
Scotland Coronary Prevention Study (WOSCOPS)
[14]. Moreover this polymorphism has been also
associated with risk to developing various CHDs in
prospective population-based reports such as the
Atherosclerosis Risk in Communities (ARIC) study
[1], Cardiovascular Health Study (CHS) [12] and the
Women’s Health Study (WHS) [7] that encompass a
broad spectrum of populations. With this evidence,
we performed a meta-analysis and systematic review
to evaluate genetic associations between the
Trp719Arg polymorphism of the KIF6 gene and
susceptibility to manifesting some CHD. 23 studies
with a total of 38,906 subjects were eligible. We con-
ducted four principal analyses in the present work.
The first one involved whole populations, the second
comprised CAD individuals, the third MI individuals
and the last ethnicity (Caucasians). It is worth noting
that none of the carried out analyses showed hetero-
geneity, therefore, this meta-analysis was conducted
with a group of studies that was homogeneous in
clinical and methodological terms and provided a
meaningful sample. In the overall analysis, we found
that in all the studies concerning this variant; the
pooled ORs suggested a possible protective role to
present CHD clinically. In the stratified analysis by
CAD, we could not find any significant association in
all the analyses performed. However, we found a pos-
sible relation between the Trp719Arg polymorphism
of the KIF6 gene and CHD in recessive genetic
models of the MI subgroup. Additionally, we con-
ducted a meta-regression analyses, where the age role
in the heterogeneity among studies in MI sample as
well as the whole sample population was explored;
this analyses showed the same outcomes obtained in
Fig. 3 Egger’s funnel plots in overall studies indicating publication bias in studies on CHD and the Trp719Arg polymorphism without
heterogeneity using the following models: a) Allelic; b) Additive; c) Dominant, and d) Recessive
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ing only Caucasian populations and we could not
find any significant association in all the analyses.
Similarly, the meta-analysis failed to find a significant
relationship between Trp719Arg and the risk of CHD
in Caucasian populations [15]. There are several
explanations for the present outcomes concerning
the lack of association of Trp719Arg with CHD.
First, there are differences in diagnosis in the popula-
tion of patients and, second, the discrepancy ofassociation between populations may be attributed
to different genetic backgrounds and environmental
factors [13, 16].
Our findings demonstrate that this polymorphism
may be a risk for heart disease development. In
addition, some limitations of the present meta-
analysis must be addressed. First, we performed the
present meta-analysis based only on published studies.
We consider that by selecting only published results,
we ensure that our meta-analysis excludes poorly
Fig. 4 Meta-regression plot showing relationship between age and the log odds ratio in all populations
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involves 23 studies, it is relatively small in comparison
with other meta-analyses on different diseases. How-
ever this limitation involved a meta-regression analysis
in order to resolve the problem. We consider that the
number of eligible studies included in our meta-analysis
is small, hence to validate our results a larger number of
studies must be included in future investigations. In the
sub-group analysis by ethnicity, we only included Cau-
casian populations but we acknowledge the importance
of theTrp719Arg polymorphism for CHD developmentFig. 5 Odds ratios and forest plots of the Trp719Arg polymorphism in CAD
a) Allelic, b) Adittive, c) Dominant and d) Recessivein Asian populations. We suggest that more studies in-
vestigating this association must be undertaken in Asian
populations.Conclusions
The present study has demonstrated that the Trp719Arg
polymorphism of the KIF6 gene is an important risk
factor for developing MI. Moreover, our findings suggest
that allele 719Arg may exert a protective association to
present CHD in all populations.population without heterogeneity using the following models:
Fig. 6 Egger’s funnel plots of the Trp719Arg polymorphism indicating publication bias in CAD population without heterogeneity using a) Allelic,
b) Adittive, c) Dominant and d) Recessive
Ruiz-Ramos et al. Hereditas  (2015) 152:3 Page 11 of 16
Fig. 7 Odds ratios and forest plots of the Trp719Arg polymorphism in MI population without heterogeneity using the following models: a) Allelic,
b) Adittive, c) Dominant and d) Recessive
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Fig. 8 Egger’s funnel plots of the Trp719Arg polymorphism indicating publication bias in MI population without heterogeneity using a) Allelic,
b) Adittive, c) Dominant and d) Recessive
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Fig. 9 Meta-regression plot showing relationship between age and the log odds ratio in MI population
Fig. 10 Odds ratios and forest plots of of the Trp719Arg polymorphism in Caucasian population without heterogeneity using the following
models: a) Allelic, b) Additive, c) Dominant and d) Recessive
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Fig. 11 Egger’s funnel plots of the Trp719Arg polymorphism indicating publication bias in Caucasian population without heterogeneity using the
following models: a) Allelic, b) Additive, c) Dominant and d) Recessive
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